Clinical trial · Observational
Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer
Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer : a Pilot Study
NCT01336231CI-TRIAL-00023196COG-ANGIOterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): lack of recruitment
Summary
Brief summary (as posted)
Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Kidney Cancer | Malignant Kidney Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- patients group
- description
- Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
Primary outcomes (1)
- measure
- Impact of fatigue, memory problems and attentional
- timeFrame
- up to 12 months after treatment
- description
- Assessing the impact of fatigue, memory problems and attentional induced by an anti-angiogenic and study their evolution over time in patients with metastatic kidney cancer.
Secondary outcomes (7)
- measure
- Parameters of quality of life
- timeFrame
- up to 12 months after treatment
- description
- Studying the different parameters of quality of life and their evolution over time.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient (e) Age (e) over 18 years * Kidney cancer metastatic or locally advanced * Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together * Proposed treatment in first line or second line * Brain imaging not finding brain metastases * Having signed the informed consent of study participation * The patient may have received prior anti-angiogenic Exclusion Criteria: * Cancer of the kidney other than primitive * Previous history of cancer other than kidney cancer in complete remission for less than 5 years * Patients under 18 years * Patients whose treatment is associated with chemotherapy * disorders of cognitive functions to existing treatment delivery * Pathology psychiatric evolutionary * Refusal of participation * Patient unable to respond to cognitive tests * Drug use * Heavy drinking (WHO criteria) * History of stroke * History of head trauma * Brain metastases known * MMS below normal compared to existing standards for age and socio-cultural
References
Publications (0)
Data not yet available
No reference posted for this study.